EMS lands in Campinas the week of its semaglutide launch and Medley acquisition push

EMS flew from Burbank, California, to Viracopos-Campinas International Airport on June 15-16, 2026, a 11-hour, 20-minute Gulfstream G650ER flight that returned its executives to company headquarters in Hortolândia.

The same week, EMS is rolling out Ozivy, the first domestic semaglutide injection pen, with commercial sales beginning June 15 per a Valor International report. The company also awaits approval from Brazil's antitrust regulator, Cade, for its $600 million acquisition of Sanofi's generics arm, Medley, as covered by InforCapital. The trip follows a June 14 positioning flight from New Jersey to Burbank, likely a stopover from the eastern U.S. where EMS has held meetings with regulators or potential partners.

EMS's previous itinerary included a June 8-11 swing from Nice to Campinas and then to New Jersey, suggesting the company's leadership has been shuttling between European business (via its Serbian subsidiary Galenika) and American financial or regulatory talks. The return to Campinas locks in focus on the Ozivy launch, capacity expansion at the Hortolândia plant, and the Cade review — the three threads that will define EMS's market position for the rest of 2026.